Keytruda

Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma

A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding[…]

Read More »

A New Study is Looking at the Combination of Keytruda and ONCOS-102

A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]

Read More »

A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients

Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]

Read More »

Keytruda is Now Approved for Mesothelioma and Other Cancers

Keytruda is now approved for certain mesothelioma patients. The immunotherapy drug has been tested for mesothelioma before, but has not been approved for the treatment of it. The approval is for adult and pediatric cancers with unresectable disease and high mutational burden that have been treated and have no other[…]

Read More »

Dendritic Cell Therapy Could be used to Treat Mesothelioma

Immunotherapy is a blossoming field that is becoming more advanced. Instead of other treatments that kill healthy cells in addition to killing cancerous cells, immunotherapy uses the body’s immune system to fight cancer cells, leaving healthy non-cancerous cells intact. It is a better treatment because it is very effective, more[…]

Read More »

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma.[…]

Read More »

New Clinical Trial Underway for Immunotherapy Treatment; CA-170

A new immunotherapy treatment that has recently been administered to a patient suffering from mesothelioma has researchers and scientists optimistic that if results are positive, this treatment could be more effective than Keytruda, the immunotherapy treatment that has had major success in non-small cell lung cancer  The name of the[…]

Read More »

Immunotherapy – What Side Effects Can You Expect?

As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural[…]

Read More »

Immunotherapy May Help Extend the Lives of Lung Cancer and Mesothelioma Patients

Immunotherapy is revolutionizing the health care industry by adding extra years of life to people with lung cancer. A few years ago it was rare for patients with an advanced stage of this disease to live past two years but today it has become more common to do so. Immunotherapy[…]

Read More »

Biomarker CD47 as a Successful Diagnostic and Treatment Tool

Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months.  A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor[…]

Read More »